Resistant Cancer: Clinical Trials

3 trials for Resistant Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 unknown. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 2, Unknown 1
Phase 21Unknown 1

Follow Resistant Cancer: new trials by email Literature Review of Resistant Cancer trials Research Report on Resistant Cancer

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Autologous CAR-T Cells Targeting B7-H3 in PDAC
iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse
Phase 1RecruitingUNC Lineberger Comprehensive Cancer Center272024-07-182026-06-08
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine - Breast Cancer, Relapse
Phase 1RecruitingUNC Lineberger Comprehensive Cancer Center422024-06-272026-07-28
Lorlatinib Combinations in Lung Cancer
Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation
Phase 1 / Phase 2UnknownMassachusetts General Hospital962020-05-012021-03-10

Narrower conditions

Recurrence (3)  ·  Breast Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Disease Attributes (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Breast Diseases (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Lung Diseases (1)  ·  Pancreatic Diseases (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Skin Diseases (1)

Interventions

Cell- and Tissue-Based Therapy (1)  ·  Crizotinib (1)  ·  Cyclophosphamide (1)  ·  binimetinib (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)  ·  lorlatinib (1)

Sponsors

UNC Lineberger Comprehensive Cancer Center (2)  ·  Massachusetts General Hospital (1)

Countries

United States (3)

Top investigators

Ashwin Somasundaram, MD (1)  ·  Ibiayi Dagogo-Jack, MD (1)  ·  Yara Abdou, MD (1)

NIH funding

P50CA058223 (1)